Last reviewed · How we verify
Period 1 - Treatment Sequence AB — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Period 1 - Treatment Sequence AB (Period 1 - Treatment Sequence AB) — Theriva Biologics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Period 1 - Treatment Sequence AB TARGET | Period 1 - Treatment Sequence AB | Theriva Biologics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Period 1 - Treatment Sequence AB CI watch — RSS
- Period 1 - Treatment Sequence AB CI watch — Atom
- Period 1 - Treatment Sequence AB CI watch — JSON
- Period 1 - Treatment Sequence AB alone — RSS
Cite this brief
Drug Landscape (2026). Period 1 - Treatment Sequence AB — Competitive Intelligence Brief. https://druglandscape.com/ci/period-1-treatment-sequence-ab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab